 |
|
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424. Published online 2022 Feb 17 DOI: https://doi.org/10.3350/cmh.2022.0012
|
|
Citations to this article as recorded by
 Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants
Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer
Clinical Pharmacology in Drug Development.2023; 12(2): 175. CrossRef Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!
David Durantel
Antiviral Research.2023; 210: 105515. CrossRef New Approaches to Chronic Hepatitis B
Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini
New England Journal of Medicine.2023; 388(1): 55. CrossRef The scientific basis of combination therapy for chronic hepatitis B functional cure
Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim
Nature Reviews Gastroenterology & Hepatology.2023;[Epub] CrossRef Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review
Jie-Li Hu, Ai-Long Huang
Microorganisms.2023; 11(3): 600. CrossRef Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; : 100738. CrossRef The progress of molecules and strategies for the treatment of HBV infection
Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials
Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Expert Opinion on Emerging Drugs.2022; 27(2): 127. CrossRef Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection
Ilaria Montali, Andrea Vecchi, Marzia Rossi, Camilla Tiezzi, Amalia Penna, Valentina Reverberi, Diletta Laccabue, Gabriele Missale, Carolina Boni, Paola Fisicaro
Biomedicines.2022; 10(6): 1224. CrossRef Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B
Mark A. Feitelson, Alla Arzumanyan, Ira Spector, Arvin Medhat
Biomedicines.2022; 10(9): 2210. CrossRef Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection
Rex Wan-Hin Hui, Lung-Yi Mak, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen
Current Hepatology Reports.2022; 21(4): 59. CrossRef State-of-the-art and emerging antivirals for chronic hepatitis B infection
Margarita Papatheodoridi, George V. Papatheodoridis
Expert Opinion on Pharmacotherapy.2022; 23(18): 1999. CrossRef
|